Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 12/2017

01-12-2017 | Review on RMDs

Urolithiasis as an extraarticular manifestation of ankylosing spondylitis

Authors: Cengiz Korkmaz, Döndü Üsküdar Cansu, John A. Sayer

Published in: Rheumatology International | Issue 12/2017

Login to get access

Abstract

Ankylosing spondylitis (AS) affects sacroiliac and axial joints as well as extraarticular organs, such as the eye, lung, bowel, and heart. Although examples of renal involvement in AS, such as IgA nephropathy, amyloidosis, and glomerulonephritis, have been reported, it has not been emphasized that urolithiasis is frequently formed in the clinical course of AS. Growing evidence indicates that urolithiasis may be observed in AS patients and is more frequent than other extraarticular features. In this review, we will discuss frequency and predictors of AS-related urolithiasis and summarize the possible underlying genetic and biochemical mechanisms. We believe an increased awareness of urolithiasis as a complication of AS will encourage future studies that will shed light on disease mechanisms and preventative therapies.
Literature
1.
Van der Heijde D (2008) Ankylosing spondylitis. In: Klippel JH, Stone JH, Crofford LJ, White PH (eds) Primer on the rheumatic disease, 13th edn. Springer, Berlin
2.
Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(Suppl 3):8–18CrossRef
3.
El Maghraoui A (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 22:554–560CrossRefPubMed
4.
Elewaut D, Matucci-Cerinic M (2009) Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology 48:1029–1035CrossRefPubMed
5.
Korkmaz C, Ozcan A, Akçar N (2005) Increased frequency of ultrasonographic findings suggestive of renal stones in patients with ankylosing spondylitis. Clin Exp Rheumatol 23:389–392PubMed
6.
Jakobsen AK, Jacobsson LT, Patschan O, Askling J, Kristensen LE (2014) Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjects. PLoS ONE 25:9
7.
Lui NL, Carty A, Haroon N, Shen H, Cook RJ, Inman RD (2011) Clinical correlates of urolithiasis in ankylosing spondylitis. J Rheumatol 38:1953–1956CrossRefPubMed
8.
Jakobsen AK, Jacobsson LT, Patschan O, Hopfgarten T, Askling J, Kristensen LE (2015) Surgical interventions for nephrolithiasis in ankylosing spondylitis and the general population. Scand J Urol 21:1–6
9.
Elian N, Berinde L, Georgescu L, Ocica I, Saba I (1972) Nephro-uropathic manifestations in ankylopoietic spondylitis. Med Interna 24:187–193
10.
Mladenovic V (1973) Nephrolithiasis in ankylosing spondylitis. Rheumatizam 20:106–110
11.
Jimenez Balderas FJ, Robles EJ, Juan L, Badui E, Arellano H, Espinosa Said L et al (1989) Purine metabolism in ankylosing spondylitis: clinical study. Arch Invest Med 20:163–170
12.
Incel NA, Gökoğlu F, Nacir B, İncel N (2006) Bone and stone in ankylosing spondylitis: osteoporosis and urolithiasis. Clin Rheumatol 25:667–670CrossRefPubMed
13.
Canales BK, Leonard SM, Singh JA, Orzano IM, Zimmermann B, Weiland D et al (2006) Spondyloarthropathy: an independent risk factor for kidney stones. J Endourol 20:542–546CrossRefPubMed
14.
Cansu DU, Calışır C, Savaş Yavaş U, Kaşifoğlu T, Korkmaz C (2011) Predictors of radiographic severity and functional disability in Turkish patients with ankylosing spondylitis. Clin Rheumatol 30:557–562CrossRefPubMed
15.
Fallahi S, Jamshidi AR, Gharibdoost F, Mahmoudi M, Paragomi P, Nicknam MH et al (2012) Urolithiasis in ankylosing spondylitis: correlation with BASDAI, BASFI and BASMI. Caspian J Intern Med 3:508–513PubMedPubMedCentral
16.
Resorlu H, Adam G, Aylanc N, Akbal A, Ozdemir H (2015) Prospective evaluation of the renal morphology and vascular resistance inpatients with ankylosing spondylitis. Med Ultrason 17:180–184CrossRefPubMed
17.
18.
19.
20.
Mielants H, Veys EM, Goemaere S, Goethals K, Cuvelier C, De Vos M (1991) Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol 18:1542–1551PubMed
21.
Pang SW, Davis JC (2006) Clinical aspects of ankylosing spondylitis. In: Weisman MH, Reveille JD, Van der Heijde D (eds) Ankylosing spondylitis and spondyloarthropathies, 1st edn. Mosby, Philadelphia, pp 145–153
22.
Mielants H, van den Bosch F (2006) Inflammatory bowel disease spondyloarthritis: epidemiology, clinical features, and treatment. In: Weisman MH, Reveille JD, Van der Heijde D (eds) Ankylosing spondylitis and spondyloarthropathies, 1st edn. Mosby, Philadelphia, pp 65–74CrossRef
23.
Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ et al (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314(5804):1461–1463CrossRefPubMedPubMedCentral
24.
Rahman P, Inman RD, Gladman DD, Reeve JP, Peddle L, Maksymowych WP (2008) Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 58:1020–1025CrossRefPubMed
25.
van Sommeren S, Janse M, Karjalainen J, Fehrmann R, Franke L, Fu J, Weersma RK (2014) Extraintestinal manifestations and complications in inflammatory bowel disease: from sharedgenetics to shared biological pathways. Inflamm Bowel Dis 20:987–994PubMed
26.
Turina MC, Sieper J, Yeremenko N, Conrad K, Haibel H, Rudwaleit M et al (2014) Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis 73:1746–1748CrossRefPubMed
27.
Matzkies FG, Targan SR, Berel D, Landers CJ, Reveille JD, McGovern DP et al (2012) Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Res Ther 14(6):R261CrossRefPubMedPubMedCentral
28.
Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J (2003) Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52:847–853CrossRefPubMedPubMedCentral
29.
Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA et al (2005) Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology 128:2020–2028CrossRefPubMed
30.
Gönüllü E, Bilge NŞ, Cansu DU, Bekmez M, Musmul A, Akçar N et al (2016) Risk factors for urolithiasis in patients with ankylosing spondylitis: a prospective case-control study. Urolithiasis. doi:10.​1007/​s00240-016-0911-8 PubMed
31.
Shodjai-Moradi E, Ebringer A, Abuljadayel I (1992) IgA antibody response to Klebsiella in ankylosing spondylitis measured by immunoblotting. Ann Rheum Dis 51:233–237CrossRefPubMedPubMedCentral
32.
Khalafpour S, Ebringer A, Abuljadayel I et al (1988) Antibodies to Klebsiella and Proteus microorganisms in ankylosing spondytitis and rheumatoid arthritis patients measured by ELISA. Br J Rheumatol 27(suppl 2):86–89CrossRefPubMed
33.
Yuan GH, Shi GY, Ding YZ (1993) Antibodies to Klebsiella pneumoniae in ankylosing spondylitis. Zhonghua Nei Ka Za Zhi 32:467–469 (in Chinese, English abstract)
34.
35.
Ardiçoğlu O, Atay MB, Ataoğlu H et al (1996) IgA antibodies to Klebsiella in ankylosing spondylitis. Clin Rheumatol 15:573–576CrossRefPubMed
36.
Muñoz-Ortego J, Vestergaard P, Rubio JB, Wordsworth P, Judge A, Javaid MK et al (2014) Ankylosing spondylitis is associated with an increased risk of vertebral and nonvertebral clinical fractures: a population-based cohort study. J Bone Miner Res 29:1770–1776CrossRefPubMed
37.
38.
Ou SM, Chen YT, Shih CJ, Tarng DC (2015) Increased risk of bone fracture among patients with urinary calculi: a nationwide longitudinal population-based study. Osteoporos Int 26:1261–1269CrossRefPubMed
39.
Klingberg E, Nurkkala M, Carlsten H, Forsblad-d’Elia H (2014) Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol 41:1349–1356CrossRefPubMed
40.
Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R et al (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60:3257–3262CrossRefPubMed
41.
Saad CG, Ribeiro AC, Moraes JC, Takayama L, Goncalves CR, Rodrigues MB, de Oliveira RM, Silva CA, Bonfa E, Pereira RM (2012) Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther 14(5):R216CrossRefPubMedPubMedCentral
42.
Gratacós J, Collado A, Filella X, Sanmartí R, Cañete J, Llena J et al (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33:927–931CrossRefPubMed
43.
Gratacós J, Collado A, Pons F, Osaba M, Sanmartí R, Roqué M et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 42:2319–2324CrossRefPubMed
44.
Pacifici R (1997) Idiopathic hypercalciuria and osteoporosis—distinct clinical manifestations of increased cytokine induces bone resorption? J Clin Endocrinol Metab 82:29–31PubMed
45.
Will R, Bhalla AK, Palmer R, Ring R, Calin A (1989) Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet II:1483–1485CrossRef
46.
Oddsson A, Sulem P, Helgason H, Edvardsson VO, Thorleifsson G, Sveinbjörnsson G et al (2015) Common and rare variants associated with kidney stones and biochemical traits. Nat Commun 14(6):7975CrossRef
47.
Curhan GC, Willett WC, Rimm EB, Stampfer MJ (1997) Family history and risk of kidney stones. J Am Soc Nephrol 8:1568–1573PubMed
48.
Stechman MJ, Loh NY, Thakker RV (2007) Genetics of hypercalciuric nephrolithiasis: renal stone disease. Ann N Y Acad Sci 1116:461–484CrossRefPubMed
49.
50.
Tsui FW, Tsui HW, Cheng EY, Stone M, Payne U, Reveille JD et al (2003) Novel genetic markers in the 5′-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum 48:791–797CrossRefPubMed
51.
Tsui HW, Inman RD, Paterson AD, Reveille JD, Tsui FW (2005) ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther 7(3):R513–R525CrossRefPubMedPubMedCentral
52.
Liu Z, Cui Y, Zhou X, Zhang X, Han J (2013) Association of mineralization-related genes TNAP and ANKH polymorphisms with ankylosing spondylitis in the Chinese Han population. Biosci Trends 7:89–92PubMed
53.
Korkmaz C, Sayer JA (2012) ANKH and renal stone formation in ankylosing spondylitis. J Rheumatol 39:1756CrossRefPubMed
54.
Ho AM, Johnson MD, Kingsley DM (2000) Role of the Mouse ank gene in control of tissue calcification and arthritis. Science 289:265–270CrossRefPubMed
55.
Russell RG (1976) Metabolism of inorganic pyrophosphate (PPi). Arthritis Rheum 19(Suppl 3):465–478CrossRefPubMed
56.
Moochhala SH, Sayer JA, Carr G, Simmons NL (2008) Renal calcium stones: insights from the control of bone mineralization. Exp Physiol 93:43–49CrossRefPubMed
57.
Carr G, Sayer JA, Simmons NL (2007) Expression and localisation of the pyrophosphate transporter, ANK, in murine kidney cells. Cell Physiol Biochem 20:507–516CrossRefPubMed
58.
Pimentel-Santos FM, Ligeiro D, Matos M, Mourão AF, Vieira de Sousa E, Pinto P et al (2012) ANKH and susceptibility to and severity of ankylosing spondylitis. J Rheumatol 39(1):131–134CrossRefPubMed
59.
Timms AE, Zhang Y, Bradbury L, Wordsworth BP, Brown MA (2003) Investigation of the role of ANKH in ankylosing spondylitis. Arthritis Rheum 48(10):2898–2902CrossRefPubMed
60.
61.
De Koninck AS, Groen LA, Maes H, Verstraete AG, Stove V, Delanghe JR (2016) Unusual type of kidney stone. Clin Lab 62:235–239CrossRefPubMed
62.
Erturk E, Casemento JB, Guertin KR, Kende AS (1994) Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy. J Urol 151:1605–1606CrossRefPubMed
63.
Yanagisawa R, Kamijo T, Nagase Y (1999) A case of drug induced urolithiasis composed of acetyl sulphapyridine associated with ulcerative colitis. Nihon Hinyokika Gakkai Zasshi 90:462–465 (Japanese) PubMed
64.
Russinko PJ, Agarwal S, Choi MJ, Kelty PJ (2003) Obstructive nephropathy secondary to sulfasalazine calculi. Urology 62(4):748CrossRefPubMed
65.
Hoffnung JM, Parker MD, Hartz JW (1982) Papillary necrosis mimicking staghorn calculi. Urology 20:325–327CrossRefPubMed
66.
Boonen A, Everens JL (2002) Ankylosing spondylitis: what is the cost to society and can it be reduced? Best Pract Res Clin Rheumatol 16:691–705CrossRefPubMed
67.
Ben-Ami H, Ginesin YI, Behar DM, Fischer D, Edoute Y, Lavy A (2002) Diagnosis and treatment of urinary tract complication in Crohn’s disease: an experience over 15 years. Can J Gastroenterol 16:225–229CrossRefPubMed
68.
Sato S, Sasaki I, Naito H, Funayama Y, Fukushima K, Shibata C et al (1999) Management of urinary complications in Crohn’s disease. Surg Today 29:713–717CrossRefPubMed
69.
Boussorra H, Sallami S, Said Y, Chebil M, Najjar T (2013) Evaluation of urinary urolithiasis in Crohn’s disease in Tunisian patients. Tunis Med 91:440–443PubMed
70.
71.
Vupputuri S, Soucie JM, McClellan W, Sandler DP (2004) History of kidney stones as a possible risk factor for chronic kidney disease. Ann Epidemiol 14:222–228CrossRefPubMed
72.
Akman T, Binbay M, Aslan R et al (2012) Long-term outcomes of percutaneous nephrolithotomy in 177 patients with chronic kidney disease: a single center experience. J Urol 187:173–177CrossRefPubMed
Metadata
Title
Urolithiasis as an extraarticular manifestation of ankylosing spondylitis
Authors
Cengiz Korkmaz
Döndü Üsküdar Cansu
John A. Sayer
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 12/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-017-3788-0

Other articles of this Issue 12/2017

Rheumatology International 12/2017 Go to the issue

Correspondence

In reply to the letter to the Editor, “HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis”

Clinical Trials

The role of land and aquatic exercise in ankylosing spondylitis: a systematic review

Correspondence

HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis: methodological issues

Validation studies

Assessment of reliability, validity, responsiveness and minimally important change of the German Hip dysfunction and osteoarthritis outcome score (HOOS) in patients with osteoarthritis of the hip

Observational Research

Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu’s arteritis

Art in RMD

Differential diagnosis of the finger swelling on Pythagoras in the “School of Athens” (1509–1511) by Raphael (1483–1520)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits